Population pharmacokinetic analysis of meropenem in Japanese adult patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 2, 2011, Pages 230-236

  Muro, T ^a   Sasaki, T ^b   Hosaka, N ^a   Umeda, Y ^a   Takemoto, S ^a   Yamamoto, H ^a   Kamimura, H ^c   Higuchi, S ^b   Karube, Y ^c  

^a ASO IIZUKA HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

antibiotics; meropenem; non linear mixed effects model; population pharmacokinetics

Indexed keywords

MEROPENEM;

ADULT; AGED; ARTICLE; BAYES THEOREM; BOOTSTRAPPING; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NONLINEAR SYSTEM; POPULATION RESEARCH;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BAYES THEOREM; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RESEARCH DESIGN; THIENAMYCINS;

EID: 79952269525     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01171.x     Document Type: Article

References (13)

1. Baldwin CM, Lyseng-Williamson KA, Keam SJ, (2008) Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs, 68, 803-838. (Pubitemid 351559562)
2. Drusano GL, (2003) Prevention of resistance: a goal for dose selection for antimicrobial agents. Clinical Infectious Diseases, 36, 42-50.
3. Craig WA, (1998) Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases, 26, 1-12. (Pubitemid 28068148)
4. Muro T, Takemoto S, Kamimura H, Karube Y, (2008) Optimal usage of meropenem based on recommended regimen derived from Monte Carlo simulation. Japanese Journal of Pharmaceutical Health Care and Sciences, 24, 764-772.
5. Mikamo H, Totsuka K, (2005) The comparison of optimized pharmacodynamic dosing strategy for meropenem using Monte Carlo simulation. The Japanese Journal of Antibiotics, 58, 159-167. (Pubitemid 40628379)
6. Kuti JK, Dandekar PK, Nightingale CH, Nicolau DP, (2003) Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. The Journal of Clinical Pharmacology, 43, 1116-1123. (Pubitemid 37174443)
7. Racine R, Grieve AP, Flühler H, (1986) Bayesian method in practice: experiences in the pharmaceutical industry. Journal of Applied Statistics, 35, 93-150.
8. Li C, Kuti JL, Nightingale CH, Nicolau DP, (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. The Journal of Clinical Pharmacology, 46, 1171-1178. (Pubitemid 44387417)
9. Tsumura R, Ikawa K, Morikawa N, et al., (2008) The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients. Journal of Chemotherapy, 20, 615-621.
10. Ikeda K, Ikawa K, Morikawa N, Miki M, et al., (2007) High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma. Journal of Chromatography B, 856, 371-375. (Pubitemid 47302913)
11. Efron B, Tibshirani R, (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science, 1, 54-77.
12. Parke J, Holford NHG, Charles BG, (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Computer Methods and Programs in Biomedicine, 56, 19-29. (Pubitemid 29125558)
13. Mouton JW, Anker JN, (1995) Meropenem clinical pharmacokinetics. Clinical Pharmacokinetics, 28, 275-286.